Hansoh Pharmaceutical Group
Market Cap
HK$214.3b
Last Updated
2020/07/03 12:36 UTC
Data Sources
Company Financials +
Executive Summary
Hansoh Pharmaceutical Group Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Hansoh Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3692's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.6%
3692
-0.7%
HK Pharmaceuticals
1.4%
HK Market
1 Year Return
50.3%
3692
19.4%
HK Pharmaceuticals
-6.6%
HK Market
Return vs Industry: 3692 exceeded the Hong Kong Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: 3692 exceeded the Hong Kong Market which returned -9.4% over the past year.
Shareholder returns
| 3692 | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | -0.7% | 1.4% |
| 30 Day | 1.1% | 7.0% | 4.6% |
| 90 Day | 36.6% | 22.0% | 11.3% |
| 1 Year | 50.3%50.3% | 21.6%19.4% | -3.7%-6.6% |
| 3 Year | n/a | 30.9%23.3% | 4.7%-5.7% |
| 5 Year | n/a | 54.9%43.0% | 8.4%-8.8% |
Price Volatility Vs. Market
How volatile is Hansoh Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Here's Why I Think Hansoh Pharmaceutical Group (HKG:3692) Might Deserve Your Attention Today1 month ago | Simply Wall St
Is Hansoh Pharmaceutical Group Company Limited (HKG:3692) A High Quality Stock To Own?2 months ago | Simply Wall St
The Hansoh Pharmaceutical Group Company Limited (HKG:3692) Analysts Have Been Trimming Their Sales ForecastsValuation
Is Hansoh Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
71.48x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 3692 (HK$36.2) is trading above our estimate of fair value (HK$12.72)
Significantly Below Fair Value: 3692 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 3692 is poor value based on its PE Ratio (70.8x) compared to the Pharmaceuticals industry average (12.6x).
PE vs Market: 3692 is poor value based on its PE Ratio (70.8x) compared to the Hong Kong market (10x).
Price to Earnings Growth Ratio
PEG Ratio: 3692 is poor value based on its PEG Ratio (3.6x)
Price to Book Ratio
PB vs Industry: 3692 is overvalued based on its PB Ratio (14.7x) compared to the HK Pharmaceuticals industry average (1.1x).
Next Steps
Future Growth
How is Hansoh Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
19.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3692's forecast earnings growth (19.7% per year) is above the savings rate (1.6%).
Earnings vs Market: 3692's earnings (19.7% per year) are forecast to grow faster than the Hong Kong market (17.5% per year).
High Growth Earnings: 3692's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3692's revenue (16.7% per year) is forecast to grow faster than the Hong Kong market (11% per year).
High Growth Revenue: 3692's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3692's Return on Equity is forecast to be high in 3 years time (23.5%)
Next Steps
Past Performance
How has Hansoh Pharmaceutical Group performed over the past 5 years?
34.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 3692 has high quality earnings.
Growing Profit Margin: 3692's current net profit margins (29.4%) are higher than last year (24.6%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 3692's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 3692's past year earnings growth to its 5-year average.
Earnings vs Industry: 3692 earnings growth over the past year (34.4%) exceeded the Pharmaceuticals industry 6%.
Return on Equity
High ROE: 3692's Return on Equity (19.6%) is considered low.
Next Steps
Financial Health
How is Hansoh Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 3692's short term assets (CN¥17.4B) exceed its short term liabilities (CN¥6.2B).
Long Term Liabilities: 3692's short term assets (CN¥17.4B) exceed its long term liabilities (CN¥290.6M).
Debt to Equity History and Analysis
Debt Level: 3692 is debt free.
Reducing Debt: 3692 has not had any debt for past 5 years.
Debt Coverage: 3692 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 3692 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Hansoh Pharmaceutical Group current dividend yield, its reliability and sustainability?
0.38%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3692's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 3692's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3692's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3692's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3692's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Huijuan Zhong (59yo)
4.58yrs
Tenure
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 4.58yrs | no data | no data | |
| VP & CFO | no data | no data | no data | |
| Executive Director | 4.33yrs | no data | no data | |
| Executive Director | 4.58yrs | no data | no data | |
| Senior Vice President | 8.33yrs | no data | no data | |
| Senior Vice President | 7.5yrs | no data | no data | |
| Senior Vice President | 11.33yrs | no data | no data | |
| Senior Vice President | 3.75yrs | no data | no data | |
| Joint Company Secretary & Senior VP | 1.92yrs | no data | no data | |
| Joint Company Secretary | 1.08yrs | no data | no data |
4.6yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 3692's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 4.58yrs | no data | no data | |
| Executive Director | 4.33yrs | no data | no data | |
| Executive Director | 4.58yrs | no data | no data | |
| Independent Non-Executive Director | 1.17yrs | no data | no data | |
| Independent Non-Executive Director | 1.17yrs | no data | no data | |
| Non-Executive Director | 4.33yrs | no data | no data | |
| Independent Non-Executive Director | 1.17yrs | no data | no data |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: 3692's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.7%.
Top Shareholders
Company Information
Hansoh Pharmaceutical Group Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hansoh Pharmaceutical Group Company Limited
- Ticker: 3692
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$214.267b
- Shares outstanding: 5.92b
- Website: https://www.hspharm.com
Number of Employees
Location
- Hansoh Pharmaceutical Group Company Limited
- 9 Dongjin Road
- Economic and Technical Development Zone
- Lianyungang
- Jiangsu Province
- 222069
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 3692 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Share | HK | HKD | Jun 2019 |
| 3KY | DB (Deutsche Boerse AG) | Yes | Ordinary Share | DE | EUR | Jun 2019 |
| 3692 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Ordinary Share | HK | HKD | Jun 2019 |
| 3692 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Ordinary Share | HK | HKD | Jun 2019 |
Biography
Hansoh Pharmaceutical Group Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients. It provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and diabetes, as well as gastrointestinal area. The company’s principal products include Mailingda, a category 1.1 drug for the treatment of chronic myelogenous leukemia; and Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xintai, Tanneng, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, Fulairui, Ruiyisheng, Hansoh Xinfu, Xinmei, Ruibote, and Zexin, which are generic drugs. It also markets and sells drugs in other therapeutic areas, including in the cardiovascular therapeutic area. The company serves pharmaceutical product distributors. It has a cooperation agreement with Viela Bio, Inc. to develop CD19 monoclonal antibody inebilizumab for the treatment of neuromyelitis optica spectrum disorder, as well as other autoimmune diseases and hematological malignancies. The company was founded in 1995 and is headquartered in Lianyungang, the People’s Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/03 12:36 |
| End of Day Share Price | 2020/07/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.